Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rubinstein

Showing results (161-170 of 179) with videos related to

Pageof 18
Sort By:
Microbiology Resource Announcements|August 27, 2025
BK polyomavirus genotype IV isolates from virus-specific T-cell therapy recipientsTiana A Walder, Heidi L Meeds, Michael S Grimley, et al.
Transplantation and Cellular Therapy|February 3, 2023
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young AdultsThomas J Galletta, Adam Lane, Carolyn Lutzko, et al.
Plos Biology|November 22, 2019
Single-cell transcriptomics of the naked mole-rat reveals unexpected features of mammalian immunityHugo G Hilton, Nimrod D Rubinstein, Peter Janki, et al.
Pediatric Blood & Cancer|May 21, 2021
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effectiveJeremy D Rubinstein, Rachana Shah, Erin H Breese, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 22, 2021
Generation of an Allelic Series at the Ahr Locus Using an Edited Recombinant ApproachRachel H Wilson, Patrick R Carney, Edward Glover, et al.
Blood Advances|November 20, 2020
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipientsAdam S Nelson, Daria Heyenbruch, Jeremy D Rubinstein, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 21, 2024
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplantRuby Khoury, Michael S Grimley, Adam S Nelson, et al.
Transplantation and Cellular Therapy|November 17, 2021
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation RecipientsJeremy D Rubinstein, Sonata Jodele, Daria Heyenbruch, et al.
Transplantation and Cellular Therapy|May 4, 2026
Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCTStella M Davies, Emily Blyth, Catherine M Bollard, et al.
Leukemia|October 31, 2022
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemiaValeria Ceolin, Erica Brivio, Harm van Tinteren, et al.
Pageof 18

Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
Microbiology Resource Announcements|August 27, 2025
BK polyomavirus genotype IV isolates from virus-specific T-cell therapy recipientsTiana A Walder, Heidi L Meeds, Michael S Grimley, et al.
Transplantation and Cellular Therapy|February 3, 2023
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young AdultsThomas J Galletta, Adam Lane, Carolyn Lutzko, et al.
Plos Biology|November 22, 2019
Single-cell transcriptomics of the naked mole-rat reveals unexpected features of mammalian immunityHugo G Hilton, Nimrod D Rubinstein, Peter Janki, et al.
Pediatric Blood & Cancer|May 21, 2021
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effectiveJeremy D Rubinstein, Rachana Shah, Erin H Breese, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|January 22, 2021
Generation of an Allelic Series at the Ahr Locus Using an Edited Recombinant ApproachRachel H Wilson, Patrick R Carney, Edward Glover, et al.
Blood Advances|November 20, 2020
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipientsAdam S Nelson, Daria Heyenbruch, Jeremy D Rubinstein, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 21, 2024
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplantRuby Khoury, Michael S Grimley, Adam S Nelson, et al.
Transplantation and Cellular Therapy|November 17, 2021
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation RecipientsJeremy D Rubinstein, Sonata Jodele, Daria Heyenbruch, et al.
Transplantation and Cellular Therapy|May 4, 2026
Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCTStella M Davies, Emily Blyth, Catherine M Bollard, et al.
Leukemia|October 31, 2022
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemiaValeria Ceolin, Erica Brivio, Harm van Tinteren, et al.
Pageof 18